Skip to content
Home/Companies/Biotech/Sengenics

Sengenics

Biotech·Singapore·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns Sengenics?

Sengenics is a Singaporean Biotech company, currently owned by Summa Equity since 2020.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Summa Equity
Investor
Summa Equity
Summa Equity Fund II · 2019 · Buyout

Key facts

HQSingapore
SectorBiotech
StatusActive

More from Summa Equity Fund II

Other portfolio companies in the same fund.

Axion Biosystems
Active
MedTechUS· 2021
G-CON Manufacturing
Exited 2025
HealthcareUS· 2021
to Bridgepoint
Holdbart
Active
ConsumerNorway· 2021
myneva
myneva
Active
SaaSGermany· 2021
Nofitech
Active
IndustrialsNorway· 2021
Infobric
Infobric
Exited 2025
SoftwareSweden· 2019
to KKR

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Sengenics?

Sengenics is currently owned by Summa Equity, through Summa Equity Fund II, since 2020.

When did Summa Equity acquire Sengenics?

Summa Equity acquired Sengenics in 2020.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue